Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Shares Of A Biotech Company That DIDN'T Make The Drug That Saved The Ebola-Infected Doctor Are Surging

Sam RoAug 21, 2014, 17:25 IST

Dr. Kent Brantly, who had contracted the ebola virus in Liberia, was released from Atlanta's Emory University Hospital after being treated with experimental drug ZMapp.

ZMapp was developed by Mapp Biopharmaceutical, a privately held company.

It's not to be confused with MAP Pharmceuticals, which was acquired by Allergan in 2013.

Tekmira Pharmaceuticals, which also has an experimental ebola drug in the works, is up by around 5% in pre-market trading. It's unclear why.

Here's the after-hours and pre-market moves in Tekmira according to MarketWatch.